Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand (scientific article (publication date: August 2013))

Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial

Q46953076

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Q24597052

Prevention of HIV-1 infection with early antiretroviral therapy

Q24634688

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

Q26859055

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Q28473903

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe

Q28730357

CD4+ count-guided interruption of antiretroviral treatment

Q29619489

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

Q33587553

Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature

Q33893797

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

Q34139859

Monitoring HIV treatment in developing countries

Q34441436

Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?

Q35185677

Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness

Q35217495

Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial

Q35541563

CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study

Q35541572

Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings

Q35636520

Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.

Q36708737

Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy

Q37043399

Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Q37371248

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

Q37773748

Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa

Q39240148

A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.

Q40187691

Assessing Resistance Costs of Antiretroviral Therapies via Measures of Future Drug Options

Q40559554

Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study

Q40782718

Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. April 2002

Q56937624

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

Q60199584

Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda

Q73563841

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy

Q77138000

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

Q77230682

Monitoring HIV treatment in the developing world

Q78454401

Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy

Q83985084

P275

Creative Commons Attribution 4.0 International

copyrighted

issue

language of work or name

English

Q1860

P921

main subject

Thailand

Q869

viral load

Q2528140

P304

page(s)

e1001494

P577

publication date

2013-08-01

P1433

published in

PLOS MEDICINE

Q1686921

P1476

title

Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand

P478

volume

Reverse relations

cites work (P2860)

Q90161657	Adaptive viral load monitoring frequency to facilitate differentiated care: a modeling study from Rakai, Uganda
Q95729886	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
Q35804785	CD4+ gain percentile curves for monitoring response to antiretroviral therapy in HIV-infected adults
Q52604813	Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.
Q28543578	Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings
Q35049762	Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa
Q34475728	Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up
Q35641893	Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda
Q30238931	Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review.
Q36015636	HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds
Q89579733	Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Q36110959	Lack of awareness of treatment failure among HIV-1-infected patients in Guinea-Bissau - a retrospective cohort study
Q92741083	Lack of effectiveness of adherence counselling in reversing virological failure among patients on long-term antiretroviral therapy in rural Uganda
Q35847158	Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis
Q35910240	No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project
Q37516995	Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study
Q40002754	Projecting the epidemiological effect, cost-effectiveness and transmission of HIV drug resistance in Vietnam associated with viral load monitoring strategies
Q64066142	Routine versus Targeted Viral Load Strategy among Patients Starting Antiretroviral in Hanoi, Vietnam
Q47573261	Selecting a viral load threshold for routine monitoring in resource-limited settings: optimizing individual health and population impact
Q37064741	Sustainable HIV treatment in Africa through viral-load-informed differentiated care.
Q38861647	Sustainable and cost-effective monitoring of patients on ART.
Q46251979	Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes
Q34508454	Viral load versus CD4⁺ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling study
Q50929251	Which strategy for ART in resource-limited settings?